View the Results of our 3min Pulse Survey, done around the JP Morgan Conference, Jan 2017

Diseases poised for breakthrough, companies to follow & key challenges in the field

Investors

NeuroRx is currently raising funds to support its ongoing clinical development of NRX-101 (Cyclurad™) for the treatment of Acute Suicidal Ideation/Behavior (ASIB) in Bipolar Depression. If you are interested in learning more about NeuroRx and opportunities to invest in the company, please contact:

 

 

Investor Relations:

Mathew Duffy

Life Science Advisors

+1 (212) 915-0685

matthew@lifesciadvisors.com

NRX-101 (Cyclurad™) is the first oral therapeutic in development for the treatment of

Acute Suicidal Ideation/Behavior (ASIB) in Bipolar Depression

Submitting Form...

The server encountered an error.

Form received.

Contact the NeuroRx Investor-Relations Team

© 2016 NeuroRx, Inc.

*This drug is investigational and not approved by the US FDA

STAY CONNECTED